The effect of glucagon-like peptide-1 receptor agonist therapy on body mass index in adolescents with severe obesity: a randomized, placebo-controlled, clinical trial

This 3-month, randomized, double-blind, placebo-controlled clinical trial evaluated the efficacy and safety of exenatide, a GLP-1 receptor agonist, in 26 adolescents aged 12–19 years with severe obesity (BMI ≥1.2 times the 95th percentile or ≥35 kg/m²). Participants received lifestyle counseling and were randomized to exenatide (twice daily) or placebo. Exenatide